Opendata, web and dolomites

Lottare GBM SIGNED

LOcalized Targeted Therapy to Avoid REcurrent GlioBlastoma Multiforme

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lottare GBM project word cloud

Explore the words cloud of the Lottare GBM project. It provides you a very rough idea of what is the project "Lottare GBM" about.

ema    pharmacology    rate    purpose    removing    strategy    doctors    added    concerted    resection    benefits    formulation    lack    aggressive    adjunct    patient    solution    safety    contributions    stakeholders    medicine    safer    personalized    tackle    pharma    slow    experiments    combined    18    investors    kill    diagnosed    survival    treatments    selectively    ip    neuro    neurosurgeons    multiforme    startup    lethal    prognosis    surgery    adoption    consideration    expectancy    cells    brings    months    gbm    oncologists    innovative    treatment    disease    cycles    deal    tissue    release       population    clinical    framework    brain    scientists    tumor    regulatory    removed    context    newly    primary    active    single    terrible    lower    toxicology    aggressiveness    12    hydrogel    unaffected    team    targtex    feasibility    protecting    conundrum    recurrence    portuguese    drug    translates    patients    weeks    small    willingness    molecule    life    binds    competition    financial    founded    covers    chemotherapy    glioblastoma    commercial    trial   

Project "Lottare GBM" data sheet

The following table provides information about the project.

Coordinator
TARGTEX SA 

Organization address
address: AVENIDA TENENTE VALADIM, N 17, 2 F
city: Torres Vedras
postcode: 2560-275
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARGTEX SA PT (Torres Vedras) coordinator 50˙000.00

Map

 Project objective

TargTex is a newly founded Portuguese startup with a novel concept to tackle the most lethal type of brain tumor – Glioblastoma Multiforme (GBM). GBM is the most common and aggressive type of primary brain tumor, with a survival rate lower than 5% after 2 years. The aggressiveness of the disease combined with the lack of effective treatments translates into a terrible prognosis to GBM patients, with a life expectancy of no more than 12 to 18 months after being diagnosed. TargTex team has developed a concerted approach, taking into consideration the needs and contributions from key stakeholders: patients, doctors and scientists. This innovative treatment (for which we have IP protecting the application) is based on a hydrogel formulation to be used as adjunct to surgery, applied after tumor resection. With a slow release from the hydrogel – over several weeks – the molecule is able to selectively kill GBM tumor cells that were not fully removed during surgery, thus offering a safer solution to neurosurgeons, who often deal with the conundrum of removing unaffected brain tissue to avoid tumor recurrence. In addition, this approach brings added benefits to the patients since the single treatment does not require further chemotherapy cycles. Most importantly, the active drug is a small molecule that binds to a specific target in GBM cells, and therefore, covers the whole patient population since it is not a personalized medicine. Our goal for the Phase 1 is to assess the technical, commercial and financial feasibility of TargTex. For that purpose, we will a) assess the regulatory framework and IP strategy to develop an adjunct to surgery in the context of GBM; 2) design the Toxicology & Safety Pharmacology experiments needed for an EMA’s Clinical Trial application; 3) assess the willingness to adoption of our solution from neuro-oncologists and neurosurgeons and 4) evaluate competition and assess the interest of investors and pharma towards our unique product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOTTARE GBM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOTTARE GBM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More